Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-FAPI-46 PET/CT in Solid Tumors
NCT06922825Phase 1Withdrawn
- Sponsor
- Eben Rosenthal
- Start
- Jan 2027
- Primary completion
- Apr 2032
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 68Ga FAPI-46 in solid tumor, sponsored by Eben Rosenthal. Primary endpoint: Correlative relationship between 68Ga-FAPI-46 and tumor uptake at Day 15. Planned start Jan 2027; status: withdrawn.
02
Drugs
68Ga FAPI-46
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06922825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06922825.